Cynapsus Therapeutics Inc. (NASDAQ:CYNA) shares reached a new 52-week high on Thursday . The stock traded as high as $39.74 and last traded at $39.66, with a volume of 5,626,511 shares traded. The stock had previously closed at $18.36.

A number of analysts have issued reports on the stock. Noble Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Cynapsus Therapeutics in a research note on Tuesday. Janney Montgomery Scott initiated coverage on shares of Cynapsus Therapeutics in a research note on Wednesday, June 15th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, BMO Capital Markets set a $30.00 price objective on shares of Cynapsus Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 16th.

The stock’s market capitalization is $492.47 million. The company has a 50-day moving average of $17.37 and a 200-day moving average of $14.47.

Cynapsus Therapeutics (NASDAQ:CYNA) last announced its earnings results on Thursday, August 11th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $1.60. Equities research analysts forecast that Cynapsus Therapeutics Inc. will post ($3.15) earnings per share for the current year.

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.